Home > Insider Trading > Filing (0001179110-21-000563)

Filing Details

Accession Number:: 0001179110-21-000563
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-12 19:12:05
Reporting Period:: 2021-01-08

Accepted Time:: 2021-01-12 19:12:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
861838	Idera Pharmaceuticals Inc.	IDRA	Biological Products, (No Disgnostic Substances) (2836)	043072298

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556327	J. John Kirby	C/O Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton PA 19341	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-01-12	1,693	$4.22	33,882	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-01-08	51,000	$0.00	51,000	$4.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
51,000		2031-01-08	No	4	A	Direct

Footnotes

Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from 4.205 to $4.232 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Of the reported securities beneficially owned, 20,125 shares are represented by unvested RSUs.
The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.